When People with Type-1 Diabetes become adults Diabetes Technology and Transition - do we need new Models?

被引:2
|
作者
Datz, Nicolin [1 ]
Kordonouri, Olga [1 ,2 ]
Danne, Thomas [1 ,2 ]
机构
[1] Kinder & Jugendkrankenhaus BULT Hannover, Abt Kinder & Jugendmed 3, Hannover, Germany
[2] Hannover Med Sch, Hannover, Germany
关键词
D O I
10.1055/a-1332-4603
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Approximately 40 % of adolescents with type 1 diabetes lose contact with specialty care at transfer to adult care, with a marked increase in risk for poor outcomes. Adolescents showed a 2,5-fold increased risk of an HbA1c level > 9 % after transfer, compared with adolescents who remained in pediatric care. While the use of modern technologies is rapidly increasing in pediatric diabetology, fewer resources are available to address the rapidly changing digital transformation of type 1 diabetes therapy in adult diabetology, not least because of the large number of patients with type 2 diabetes who require care. Therefore, in the transition from children with type 1 diabetes to adult medicine, disparities in resource provision for training and interpretation of new diabetes technologies now add to the problems that have been known for many years. One possible solution would be the creation of regional treatment centers with pediatric and internal medicine care for people with intensive diabetes therapy and use of diabetes technology, as well as the use of telemedicine capabilities. International comparisons show that in centers where pediatric and internal medicine diabetes teams provide age-appropriate care within the same treatment facility, the transition is much less complicated and people with type 1 diabetes benefit from shared experience in the use of diabetes technologies across the lifespan. However, the implementation of such concepts under the framework of the German health care system requires a rethinking among the involved stakeholders and does not seem promising without pressure from the affected people with type 1 diabetes. Thieme. All rights reserved.
引用
收藏
页码:1200 / 1205
页数:6
相关论文
共 50 条
  • [1] Do we need new treatments for type 2 diabetes?
    Gomez-Peralta, Fernando
    Abreu Padin, Cristina
    ENDOCRINOLOGIA Y NUTRICION, 2014, 61 (06): : 323 - 328
  • [2] When do we need to suspect maturity onset diabetes of the young in patients with type 2 diabetes mellitus?
    Ustay, Ozlem
    Apaydin, Tugce
    Elbasan, Onur
    Polat, Hamza
    Gunhan, Gizem
    Dincer, Ceyda
    Seker, Lamia
    Ates, Esra Arslan
    Yabaci, Aysegul
    Guney, Ahmet Ilter
    Yavuz, Dilek Gogas
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2022, 66 (01): : 32 - 39
  • [3] Polyneuropathy in type 1 and type 2 diabetes: do we need different examinations?
    Gdynia, Hans-Juergen
    Ludolph, Albert C.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2010, 26 (02) : 107 - 108
  • [5] Do we need screening for microalbuminuria in Type 2 diabetes?
    Seereiner, S
    Rakovac, I
    Habacher, W
    Beck, P
    Gfrerer, R
    Pieber, TR
    DIABETOLOGIA, 2002, 45 : A309 - A309
  • [6] Dapagliflozin - do we need it registered for type 2 diabetes?
    Doggrell, Sheila A.
    Tuli, Rinku
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (11) : 1631 - 1635
  • [7] TRANSGENIC MOUSE MODELS OF TYPE-1 DIABETES
    LIPES, MA
    EISENBARTH, GS
    DIABETES, 1990, 39 (08) : 879 - 884
  • [8] Diabetes Technology Use in Adults with Type 1 and Type 2 Diabetes
    Kravarusic, Jelena
    Aleppo, Grazia
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2020, 49 (01) : 37 - +
  • [9] Do we need new drugs for the treatment of type2 diabetes mellitus?
    Vervoort, G.
    Tack, C. J.
    NETHERLANDS JOURNAL OF MEDICINE, 2007, 65 (05): : 157 - 159